Micaela Rodine
Papers
1
Total Citations
2
H-Index
1
About
Dr. Micaela Rodine is a pioneering oncologist whose work centers on harnessing the immune system to combat triple-negative breast cancer (TNBC), one of the most aggressive and treatment-resistant subtypes. Her major contribution lies in designing innovative immunotherapy combinations for high-risk patients. Her most-cited study, a randomized phase II trial, explores the peri-operative use of ipilimumab and nivolumab—immune checkpoint inhibitors—alongside cryoablation in women with residual TNBC after standard neoadjuvant chemotherapy. This approach aims to prime the immune system to eliminate remaining tumor cells, potentially reducing recurrence. While early in citation impact (2 citations), this work has been presented at major oncology meetings, signaling its novelty and clinical promise. Dr. Rodine’s research bridges the gap between immunotherapy and local tumor ablation, offering a new paradigm for treating early-stage, resectable disease. Her efforts are shaping future trials and providing hope for patients who currently face limited options after standard therapy.
Research Focus
Key Achievements
Top Papers
- 1